Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.50 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3362899 | 0.99 | L3MBTL1 (0.50) | L3MBTL1CACNA1HCACNA1BSERPINE1PTPN1 | |
| SCHEMBL3365881 | 0.88 | CACNA1B (0.61) | L3MBTL1CACNA1HCACNA1BSERPINE1PTPN1 | |
| SCHEMBL3365014 | 0.87 | LSS (0.53) | L3MBTL1CACNA1HCACNA1BSERPINE1PTPN1 | |
| SCHEMBL3366991 | 0.87 | CACNA1B (0.60) | L3MBTL1CACNA1HCACNA1BSERPINE1PTPN1 | |
| SCHEMBL3365715 | 0.86 | LSS (0.54) | L3MBTL1CACNA1HCACNA1BSERPINE1 | |
| SCHEMBL3368253 | 0.85 | FFAR1 (0.57) | L3MBTL1CACNA1HCACNA1BHPGDTDP1 | |
| SCHEMBL3368206 | 0.84 | CACNA1H (0.49) | L3MBTL1CACNA1HCACNA1BSERPINE1PTPN1 | |
| SCHEMBL3366887 | 0.84 | CACNA1H (0.49) | L3MBTL1CACNA1HCACNA1BSERPINE1PTPN1 | |
| SCHEMBL3365815 | 0.84 | L3MBTL1 (0.54) | L3MBTL1HPGDTDP1FFAR1MMP9 | |
| SCHEMBL3363429 | 0.84 | LSS (0.49) | L3MBTL1CACNA1HCACNA1BSERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303503-B1 | ANILINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | disclosed |
| CN-1208329-C | Novel aniline derivative | HOFFMANN LA ROCHE (CH) | 2005-06-29 | — | — | CN | disclosed |
| US-6683201-B2 | FOR THERAPY AND PROPHYLAXIS OF HYPERCHOLESTEROLEMIA, HYPERLIPEMIA, ARTERIOSCLEROSIS, VASCULAR DISEASES, MYCOSES, PARASITE INFECTIONS, GALLSTONES, TUMORS AND/OR HYPERPROLIFERATIVE DISORDERS, DIABETES | HOFFMANN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| CN-1443179-A | Aniline derivatives | HOFFMANN LA ROCHE (CH) | 2003-09-17 | — | — | CN | disclosed |
| EP-1303503-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-03-28 | — | — | US | disclosed |
| WO-2002006189-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | LSS, CYP51A1, CYP46A1 | L3MBTL1 1316/4885CACNA1H 1926/4885CACNA1B 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.